Erratum: Primary aldosteronism and impaired natriuresis in mice underexpressing TGF (Proceedings of the National Academy of Sciences of the United States of America (2013) 110 (5600-5605) DOI: 10.1073/pnas.1302641110);Primary aldosteronism and impaired natriuresis in mice underexpressing TGFβ1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages 5600-5605

  Kakoki, Masao ^a   Pochynyuk, Oleh M ^b   Hathaway, Catherine M ^a   Tomita, Hirofumi ^a   Hagaman, John R ^a   Kim, Hyung Suk ^a   Zaika, Oleg L ^b   Mamenko, Mykola ^b   Kayashima, Yukako ^a   Matsuki, Kota ^a   Hiller, Sylvia ^a   Li, Feng ^a   Xu, Longquan ^a   Grant, Ruriko ^a   Bertorello, Alejandro M ^c   Smithies, Oliver ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hyperthermia; Idiopathic bilateral adrenal hyperplasia

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; AMILORIDE; ANGIOTENSIN II; ELECTROLYTE; EPITHELIAL SODIUM CHANNEL; MESSENGER RNA; MINERALOCORTICOID; RENIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; WATER;

ADRENAL GLAND; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HYPERTENSION; MALE; MOUSE; NATRIURESIS; NONHUMAN; PLASMA RENIN ACTIVITY; PLASMA VOLUME; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; URINE VOLUME;

EID: 84875834648     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1305878110     Document Type: Erratum

References (24)

1. Cordenonsi M, et al. (2003) Links between tumor suppressors: p53 is required for TGFbeta gene responses by cooperating with Smads. Cell 113(3):301-314.
2. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29(2):117-129.
3. Zhou L, et al. (2008) TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453(7192):236-240.
4. Muraoka RS, et al. (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109(12):1551-1559.
5. Yang X, et al. (1999) Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 18(5):1280-1291.
6. Janssens K, ten Dijke P, Janssens S, Van Hul W (2005) Transforming growth factorbeta1 to the bone. Endocr Rev 26(6):743-774.
7. Clouthier DE, Comerford SA, Hammer RE (1997) Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice. J Clin Invest 100(11):2697-2713.
8. Mustoe TA, et al. (1987) Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science 237(4820):1333-1336.
9. Shull MM, et al. (1992) Targeted disruption of the mouse transforming growth factorbeta 1 gene results in multifocal inflammatory disease. Nature 359(6397):693-699.
10. Kulkarni AB, et al. (1993) Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90(2): 770-774.
11. Schultz JE, et al. (2002) TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109(6):787-796.
12. Guzik TJ, et al. (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204(10):2449-2460.
13. Cambien F, et al. (1996) Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 28(5):881-887.
14. Niu W (2011) Evaluation of transforming growth factor beta-1 gene 869T/C polymorphism with hypertension: A meta-analysis. Int J Hypertens 2011:934265.
15. Yan-Yan L (2011) Transforming growth factor β1 +869T/C gene polymorphism and essential hypertension: A meta-analysis involving 2708 participants in the Chinese population. Intern Med 50(10):1089-1092.
16. Derynck R, Jarrett JA, Chen EY, Goeddel DV (1986) The murine transforming growth factor-beta precursor. J Biol Chem 261(10):4377-4379.
17. Kakoki M, et al. (2004) Altering the expression in mice of genes by modifying their 3' regions. Dev Cell 6(4):597-606.
18. Inoue N, et al. (1995) Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta1. Arterioscler Thromb Vasc Biol 15(8): 1255-1261.
19. Nagata D, et al. (2006) Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48(1):165-171.
20. Vodovotz Y, et al. (1996) Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. J Exp Med 183(5):2337-2342.
21. Liakos P, Lenz D, Bernhardt R, Feige JJ, Defaye G (2003) Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression. J Endocrinol 176(1):69-82.
22. Le Roy C, Li JY, Stocco DM, Langlois D, Saez JM (2000) Regulation by adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-beta, and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity and expression of ACTH receptor, steroidogenic acute regulatory protein, cytochrome P450c17, and 3betahydroxysteroid dehydrogenase. Endocrinology 141(5):1599-1607.
23. Sarafidis PA, Bakris GL (2008) Resistant hypertension: An overview of evaluation and treatment. J Am Coll Cardiol 52(22):1749-1757.
24. Calhoun DA, et al.; American Heart Association Professional Education Committee (2008) Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the american heart association professional education committee of the council for high blood pressure research. Circulation 117(25):e510-e526.